Severe interstitial lung disease associated with amrubicin treatment

Journal of Thoracic Oncology

Volumn 5, Issue 9, 2010, Pages 1435-1438

  Yoh, Kiyotaka ^a   Kenmotsu, Hirotsugu ^a   Yamaguchi, Yoko ^a   Kubota, Kaoru ^a   Ohmatsu, Hironobu ^a   Goto, Koichi ^a   Niho, Seiji ^a   Ohe, Yuichiro ^a   Saijo, Nagahiro ^a   Nishiwaki, Yutaka ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Amrubicin; Chemotherapy; Interstitial lung disease; Small cell lung cancer; Toxicity

Indexed keywords

AMRUBICIN; METHYLPREDNISOLONE;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DRUG EFFICACY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG INFILTRATE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESPIRATORY FAILURE; SMOKING;

EID: 77956269123     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e369a8     Document Type: Article

References (19)

1. Hanada M, Mizuno S, Fukushima A, et al. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 1998;89:1229-1238.
2. Yamaoka T, Hanada M, Ichii S, et al. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 1998;89:1067-1073.
3. Suzuki T, Minamide S, Iwasaki T, et al. Cardiotoxicity of a new anthracy-cline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin. Invest New Drugs 1997;15:219-225.
4. Noda T, Watanabe T, Kohda A, et al. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 1998;16:121-128.
5. Morisada S, Yanagi Y, Noguchi T, et al. Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 1989;80:69-76.
6. Bosch X. Small-cell lung cancer responds to amrubicin. Lancet Oncol 2007;8:13.
7. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366: 1385-1396.
8. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:5448-5453.
9. Jotte RM, Conkling PR, Reynolds C, et al. A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy. J Clin Oncol 2008;26:8040.
10. Sawa T, Yana T, Takada M, et al. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial. Invest New Drugs 2006;24:151-158.
11. Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007;25:253-258.
12. Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008;133:528-538.
13. Pavlakis N, Bell DR, Millward MJ, et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997;80:286-291.
14. Michielin O, Udry E, Periard D, et al. Irinotecan-induced interstitial pneumonia. Lancet Oncol 2004;5:322-324.
15. Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002;94:847-853.
16. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-139.
17. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:5401-5406.
18. Ettinger DS, Jotte RM, Gupta V, et al. A phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy. J Clin Oncol 2008;26:8041.
19. Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008;177:1348-1357.